Oslo, Norway, November 9, 2017 – Prof. Kjetil Taskén, MD, PhD has notified PCI Biotech Holding ASA’s Nomination Committee and Board of Directors that he is not able to be a candidate for re-election as Director of PCI Biotech Holding ASA’s Board of Directors at the next ordinary general meeting, in May 2018. Prof. Taskén has recently been appointed Head of Institute for Cancer Research at Oslo University Hospital and is therefore not able to continue as a Director of PCI Biotech Holding ASA’s Board of Directors. Prof. Taskén has served as a Director since October 2008.
“Professor Taskén’s deep knowledge about immunology and cancer has been of immeasurable value to PCI Biotech. We thank Kjetil for his many years of service on the Board of Directors and congratulate him on his new position”, said Hans Peter Bøhn, the Chairman of the Board of Directors.
The Nomination Committee of PCI Biotech Holding ASA is responsible for submitting a recommendation to the General Meeting for the election of the Board of Directors. Jónas Einarsson is Chairman of the Nomination Committee of PCI Biotech Holding ASA.
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com
Per Walday, CEO, email@example.com, Mobile: +47 917 93 429.